The Clix Group LLC – Trademark Portfolio

Entity Type: 16

The Clix Group LLC holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include PAYCLIX and ACCEPT OR REJECT. The owner is based in Beaverton, OR.

14513 SW Grayling Lane

Beaverton, OR 97007

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

The Clix Group LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

36
Insurance & Financial (3 filings)

Insurance; financial affairs; monetary affairs; real estate affairs

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does The Clix Group LLC have?

The Clix Group LLC has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 2 cancelled.

What trademark classes does The Clix Group LLC file in?

The Clix Group LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 42 (Computer & Scientific). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.

What are The Clix Group LLC's most well-known trademarks?

The Clix Group LLC's registered trademark portfolio includes well-known marks such as PAYCLIX and ACCEPT OR REJECT. These are among 2 currently registered trademarks in the portfolio.

What is The Clix Group LLC's trademark registration success rate?

The Clix Group LLC has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.